miRNA Plasmid Composition for Complement and Factor Downregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulation of bioactive molecules such as complements and factors leads to homeostatic imbalance, resulting in disease, and existing therapies are inadequate for effectively regulating their expression.
Innovation Solution
Compositions comprising recombinant plasmids that encode for micro-interfering ribonucleic acid (miRNA) sequences are administered to upregulate miRNA production, targeting and degrading or inactivating the mRNA of specific biomolecules like complements and factors, thereby reducing their bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to regulate bioactive molecule expression, then treatment is provided, but the regulation effectiveness is inadequate
Solution Approach 1:
The patent introduces miRNA as an intermediary molecule that mediates the regulation of bioactive molecules. The recombinant plasmid encodes miRNA sequences that specifically target and bind to mRNA of complement and factor proteins, preventing their translation and effectively downregulating their expression. This intermediary mechanism provides reliable and adaptable regulation that existing therapies lack.
Solution Approach 2:
The patent changes the regulatory parameter from direct protein inhibition to post-transcriptional gene silencing via miRNA. By modifying the expression level of miRNA through recombinant plasmid administration, the system achieves precise control over bioactive molecule production, improving both regulation effectiveness and adaptability to different disease states.
2Quantity of substance
If miRNA production is upregulated to degrade target mRNA, then bioavailability of target biomolecule decreases, but this requires effective delivery and expression systems
Solution Approach 1:
The patent employs preliminary action by designing recombinant plasmids that are pre-configured with miRNA encoding sequences, promoters, and regulatory elements before administration. The plasmids are prepared in advance to ensure proper expression once delivered to cells, simplifying the overall delivery system while achieving high miRNA production levels for effective mRNA degradation.
3Stability of the object's composition
If homeostasis is restored by downregulating over-expressed bioactive molecules, then disease is treated, but precise control of downregulation is needed
Solution Approach 1:
The patent implements feedback control through the natural regulatory mechanism of miRNA-mRNA interaction. The miRNA encoded by the recombinant plasmid specifically binds to complementary sequences in target mRNA, providing negative feedback that automatically adjusts protein expression levels. This feedback mechanism restores homeostasis with precise control, as the system responds dynamically to the actual expression levels of bioactive molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively downregulate the production of target biomolecules, restoring homeostasis and potentially treating associated diseases by increasing miRNA production within cells.
Implementation Method 1
The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated
Implementation Method 2
The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA)
Implementation Method 3
a backbone sequence of nucleic acids that facilitates introduction of the one or more insert sequences into one or more of a subject's cells where it is expressed and/or replicated
Data Source
AI summary
Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a complement or a factor. In some embodiments of the present disclosure, the target biomolecule is a complement such as complement C1q, complement C1r, complement C1s, complement C3 or complement C5. In some embodiments of the present disclosure, the target biomolecule is a factor such as Factor B, Factor D or Factor 10.